236 related articles for article (PubMed ID: 36269388)
21. Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma.
Wu Q; Chen L; Miao D; Jin Y; Zhu Z
Sci Rep; 2022 Feb; 12(1):3079. PubMed ID: 35197523
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma.
Yuan H; Liu J; Zhao L; Wu P; Chen G; Chen Q; Shen P; Yang T; Fan S; Xiao B; Jiang K
Front Immunol; 2021; 12():800268. PubMed ID: 34956238
[TBL] [Abstract][Full Text] [Related]
23. Establishment and validation of a ubiquitination-related gene signature associated with prognosis in pancreatic duct adenocarcinoma.
Guo Y; Wu Z; Cen K; Bai Y; Dai Y; Mai Y; Hong K; Qu L
Front Immunol; 2023; 14():1171811. PubMed ID: 37359528
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Implications of an Autophagy-related Gene Signature in Pancreatic Ductal Adenocarcinoma.
Liu WS; Feng YX; Li SN; Shao YJ; Wang K
Am J Clin Oncol; 2022 Mar; 45(3):95-104. PubMed ID: 35195559
[TBL] [Abstract][Full Text] [Related]
25. A Signature of N
Chen J; Lu T; Zhong F; Lv Q; Fang M; Tu Z; Ji Y; Li J; Gong X
Front Immunol; 2022; 13():809872. PubMed ID: 35185897
[TBL] [Abstract][Full Text] [Related]
26. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
27. Identification of a potential prognostic model combining pyroptosis-related gene with immune microenvironment for pancreatic ductal adenocarcinoma.
Xie H; Xu J; Zhao Q
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17175-17187. PubMed ID: 37782328
[TBL] [Abstract][Full Text] [Related]
28. A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma.
Yang H; Zhang W; Ding J; Hu J; Sun Y; Peng W; Chu Y; Xie L; Mei Z; Shao Z; Xiao Y
Front Immunol; 2022; 13():970588. PubMed ID: 36148233
[TBL] [Abstract][Full Text] [Related]
29. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma.
Liu J; He M
Int Immunopharmacol; 2024 May; 134():112266. PubMed ID: 38761784
[TBL] [Abstract][Full Text] [Related]
30. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
31. Values of a novel pyroptosis-related genetic signature in predicting outcome and immune status of pancreatic ductal adenocarcinoma.
Xu X; Liang JH; Li JH; Xu QC; Yin XY
Gastroenterol Rep (Oxf); 2022; 10():goac051. PubMed ID: 36196256
[TBL] [Abstract][Full Text] [Related]
32. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment.
Du Y; Ma Y; Zhu Q; Liu T; Jiao Y; Yuan P; Wang X
Front Pharmacol; 2021; 12():707930. PubMed ID: 34248650
[No Abstract] [Full Text] [Related]
33. Single-cell and bulk RNA sequencing identifies T cell marker genes score to predict the prognosis of pancreatic ductal adenocarcinoma.
Zheng H; Li Y; Zhao Y; Jiang A
Sci Rep; 2023 Mar; 13(1):3684. PubMed ID: 36878969
[TBL] [Abstract][Full Text] [Related]
34. Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma.
Wang Y; Ji Y; Xu Q; Huang W
Front Genet; 2022; 13():866340. PubMed ID: 36226185
[No Abstract] [Full Text] [Related]
35. Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma.
Zhu ZG; Chen L; Miao DL; Jin Y; Wu Q
Front Genet; 2022; 13():941389. PubMed ID: 36046234
[No Abstract] [Full Text] [Related]
36. Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Wang W; Hua J; Xu J; Liang C; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Oncol; 2021; 11():643465. PubMed ID: 33912458
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
[No Abstract] [Full Text] [Related]
38. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
40. Systematic Analysis of Alternative Splicing Landscape in Pancreatic Adenocarcinoma Reveals Regulatory Network Associated with Tumorigenesis and Immune Response.
Lu J; Wei S; Lou J; Yin S; Zhou L; Zhang W; Zheng S
Med Sci Monit; 2020 Jul; 26():e925733. PubMed ID: 32706768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
